PRFX Total Utang marang Modal PainReform Corp

Lambang korporat lan logo PainReform Ltd. (PRFX)

PainReform Ltd. (PRFX) is currently actively developing PRF-110, a drug aimed at reducing opioid load in postoperative pain management. The business relies on robust patent protection and a unique method for reducing dependence on narcotic substances. Market price visualization on GURU.Markets shows that the debt-to-equity ratio is 0.00, while the firm's success depends on regulatory approval and the adoption of the technology by surgeons.

PRFX: Total Utang marang Modal PainReform 04.07.2022 - 28.10.2026

Rincian analitis lan laporan data perusahaan PainReform Corp (PRFX)

- rega lan prakiraan konsensus rega:
Bagan rega PainReform|PRFX - Bagan tingkat prakiraan
- data kapitalisasi pasar:
Kapitalisasi pasar PainReform|PRFX - Nilai Dipunlarasaken Utang lan Kas
- data kapitalisasi buku:
Nilai Buku saben Saham PainReform|PRFX - Kapitalisasi Buku|Rasio Nilai Pasar marang Nilai Buku painreform.com|PRFX - Nilai Agregat Aset
- data utang lan likuiditas:
Utang marang Ekuitas PainReform Ltd.|PRFX - Rasio utang jangka dawa marang ekuitas|Utang jangka cendhak marang modal PainReform Ltd.|PRFX - Gunggung utang perusahaan|Utang marang nilai buku PainReform
Analisis komprehensif perusahaan:PRFX - PainReform
Produk merek PainReform Corp

This indicator measures the proportion of borrowed funds relative to equity, allowing investors to assess the degree of debt load and the business's financial autonomy. By analyzing the debt-to-equity ratio, one can understand how the strategy of PainReform Ltd. (PRFX) to delegate production and logistics to third-party partners reduces the need for capital expenditures and impacts the company's overall credit dependence.

Pesaing wigati

Utang marang Ekuitas Haleon HLN|Utang Agregat marang Ekuitas Kenvue Inc|Verona Pharma Corp (VRNA) - Total Utang marang Modal|Rasio Kabeh Utang marang Dana Pribadi Jyong Bio (MENS)|Total Utang marang Modal LGND (Ligand Pharmaceuticals)|amneal.com - Total Utang marang Modal|Utang marang Ekuitas Perrigo (PRGO)|ALVO: Rasio Kabeh Utang marang Dana Pribadi|LQDA (Liquidia Technologies) - Utang marang Ekuitas|Galapagos Corp (GLPG) - Rasio Total Utang marang Ekuitas|ANIP (ANI Pharmaceuticals) - Total Utang marang Modal|Total Utang marang Modal mannkindcorp.com (MNKD)|Amphastar Pharmaceuticals, Inc. (AMPH) - Rasio Total Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi PCRX (Pacira Pharmaceuticals)|SPRY: Utang marang Ekuitas|TBPH - Utang marang Modal|Rasio Total Utang marang Ekuitas Aquestive Therapeutics AQST|SCPH - Utang Agregat marang Modal|Total Utang marang Modal tectonictx.com TECX|Tonix Pharma (TNXP) - Rasio Kabeh Utang marang Dana Pribadi|Total Utang marang Modal SXTC (SXT Pharmaceuticals)|Utang marang Modal EPRX|BioHarvest Sciences (BHST) - Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi EXOZ (invizyne.com)|Oramed Pharmaceuticals Inc. (ORMP) - Utang marang Ekuitas|Utang Agregat marang Ekuitas Entera Bio Ltd ENTX|MindWalk - Total Utang marang Modal|ABVC - Total Utang marang Modal|Cumberland Pharmaceuticals - Total Utang marang Modal|QNTM (quantumbiopharma.com) - Koefisien Total Utang marang Modal|Utang marang Ekuitas FibroGen (FGEN)|Rasio Utang marang Ekuitas TELO|Rani Therapeutics (RANI) - Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi synergychc.com (SNYR)|RLYB: Total Utang marang Modal|Utang marang Modal Lexaria Bioscience Corp LEXX|Total Utang marang Modal Pulmatrix|PTHL: Utang Agregat marang Ekuitas|Utang marang Ekuitas APM|LYRA (Lyra Therapeutics Inc) - Utang marang Modal|IBO - Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi TNFA|Utang marang Ekuitas YCBD (cbdMD, Inc.)|Rasio Total Utang marang Ekuitas altamiratherapeutics.com CYTO|Rasio Total Utang marang Ekuitas Lipella|OptiNose Corp - Rasio Kabeh Utang marang Dana Pribadi|PIRS - Utang marang Ekuitas|procapsgroup.com (PROC) - Utang marang Ekuitas|PTPI - Rasio Total Utang marang Ekuitas|Qilian International Holding Group (QLI) - Utang Agregat marang Modal|Total Utang marang Modal ACELYRIN, Inc. (SLRN)|Rasio Utang marang Ekuitas TFF Pharmaceuticals, Inc (TFFP)